High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

@inproceedings{Hill2017HighSV,
  title={High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C},
  author={Andrew Hill and Giten Khwairakpam and James Wang and Sergey V. Golovin and Julia Dragunova and Rachel Smith and Vicky Houghton-Price and Roxanna Korologou-Linden and Sanjay R. Nath and Anna E. Savage and Greg Jefferys},
  booktitle={Journal of virus eradication},
  year={2017}
}
BACKGROUND High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China, Bangladesh or Egypt. This analysis assessed the efficacy of generic imported DAAs. METHODS Patients sourced generic versions of sofosbuvir (SOF), ledipasvir (LDV) and daclatasvir (DCV) from… CONTINUE READING